Trials / Completed
CompletedNCT01598051
Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan
Treatment Satisfaction Under Rivaroxaban (ACTS/TSQM)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 741 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to understand if Rivaroxaban can improve treatment satisfaction of Warfarin patients and assess the safety and effectiveness of Xarelto in real clinical practice. A total of 725 patients are to be enrolled and followed for a 6 months.period. QOL survey will be conducted at month 0, 3, 6 using ACTS/TSQM. This study is categorized as a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Xarelto for SPAF.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivaroxaban (Xarelto_ BAY59-7939) | Patients treated with Xarelto under practical manner for SPAF. |
Timeline
- Start date
- 2012-05-31
- Primary completion
- 2016-06-09
- Completion
- 2017-03-31
- First posted
- 2012-05-15
- Last updated
- 2019-05-30
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01598051. Inclusion in this directory is not an endorsement.